Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
piggyBac CAR-T for CD19-positive acute lymphoblastic leukemia
jRCTa040190099Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous piggyBac-mediated anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Dose-limiting toxicity incidence. Started Jul 2018; status: active, not recruiting.
02
Drugs
autologous piggyBac-mediated anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTa040190099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa040190099.